NASDAQ: BBIO
Bridgebio Pharma Inc Stock Ownership - Who owns Bridgebio Pharma?

Insider buying vs selling

Have Bridgebio Pharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jennifer E. CookDirector2026-06-2417,167$16.75
$287.55kBuy
Jennifer E. CookDirector2026-06-2437,167$70.00
$2.60MSell
Jennifer E. CookDirector2026-06-2420,000$8.45
$169.00kBuy
Jennifer E. CookDirector2026-06-232,196$68.57
$150.58kSell
Hannah ValantineDirector2026-06-232,196$68.57
$150.58kSell
Hannah ValantineDirector2026-06-222,808$68.00
$190.94kSell
Hannah ValantineDirector2026-06-222,808$41.73
$117.18kBuy
Charles J. HomcyDirector2026-06-20788$66.27
$52.22kSell
Jennifer E. CookDirector2026-06-151,503$67.14
$100.91kSell
Jennifer E. CookDirector2026-06-1565,921$8.45
$557.03kBuy

1 of 22

BBIO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when BBIO insiders and whales buy or sell their stock.

BBIO Shareholders

What type of owners hold Bridgebio Pharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Kkr Group Partnership LP18.84%36,900,661$2.57BInsider
Viking Global Performance LLC13.59%26,620,991$1.86BInsider
Viking Global Investors LP9.47%18,555,375$1.29BInsider
Blackrock Inc7.25%14,207,757$990.14MInstitution
Kohlberg Kravis Roberts Co LP6.77%13,260,971$924.16MInstitution
Kkr Genetic Disorder LP6.77%13,260,971$924.16MInsider
Janus Henderson Group PLC6.73%13,179,013$918.45MInstitution
Viking Global Investors LP6.05%11,842,434$825.30MInstitution
Farallon Capital Management LLC4.78%9,365,463$652.68MInstitution
Vanguard Portfolio Management LLC4.13%8,080,573$563.14MInstitution

1 of 3

BBIO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
BBIO64.70%35.30%Net SellingNet Selling
EXEL94.86%5.14%Net SellingNet Selling
JAZZ29.89%70.11%Net SellingNet Selling
IONS96.91%3.09%Net SellingNet Selling
AXSM62.19%37.81%Net SellingNet Selling

Bridgebio Pharma Stock Ownership FAQ

Who owns Bridgebio Pharma?

Bridgebio Pharma (NASDAQ: BBIO) is owned by 99.38% institutional shareholders, 54.23% Bridgebio Pharma insiders, and 0.00% retail investors. Kkr Group Partnership LP is the largest individual Bridgebio Pharma shareholder, owning 36.90M shares representing 18.84% of the company. Kkr Group Partnership LP's Bridgebio Pharma shares are currently valued at $2.59B.

If you're new to stock investing, here's how to buy Bridgebio Pharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.